GURU.Markets stock price, segment price, and overall market index valuation
The company's share price argenx SE
Argenx is a biotech company focused on treating rare autoimmune diseases. Its stock price is a classic biotech story: highly volatile, dependent on clinical trial results and regulatory approvals, with any success potentially leading to explosive growth.
Share prices of companies in the market segment - Pharma immune
Argenx is a biotech company specializing in the treatment of rare autoimmune diseases. We classify it as a Pharma-Immune company, and the chart below shows the overall performance of this segment, not just Argenx stock.
Broad Market Index - GURU.Markets
Argenx is a global immunology company developing antibody-based therapies for the treatment of severe autoimmune diseases. Its innovations earn it a spot in the GURU.Markets index. The chart below represents the market. See how clinical trial successes are impacting Argenx shares.
Change in the price of a company, segment, and market as a whole per day
ARGX - Daily change in the company's share price argenx SE
Argenx is a Dutch biotech company specializing in the development of antibody-based drugs for the treatment of autoimmune diseases. Its daily price change reflects the high volatility of the biotech sector. This metric is important for formulas on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma immune
Argenx SE is a biotech company focused on rare autoimmune diseases. This chart highlights the high volatility of the entire sector. Comparing this to Argenx's performance helps us understand how the success of its key drug makes it less dependent on overall industry trends.
Daily change in the price of a broad market stock, index - GURU.Markets
Argenx is a Belgian biopharmaceutical company specializing in drugs for the treatment of rare autoimmune diseases. The biotech sector is known for its high volatility. The chart below shows the average daily fluctuations in this industry, allowing one to assess how Argenx's performance compares to overall trends.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization argenx SE
Argenx is a Belgian biotech company that has made a breakthrough in the treatment of rare autoimmune diseases. Its year-over-year performance reflects the commercial success of its first drug and investor confidence in the potential of its scientific platform, as illustrated by the chart below.
Annual dynamics of market capitalization of the market segment - Pharma immune
Argenx SE is a biopharmaceutical company focused on developing drugs to treat rare autoimmune diseases. Its success is based on an innovative antibody development platform. This chart shows how its scientific breakthroughs and commercial potential compare to those of larger, more diversified pharmaceutical companies.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Argenx is a biopharmaceutical company specializing in the treatment of rare autoimmune diseases. Its growth, like that of other biotech companies, depends on the success of its drugs and clinical trials. It's a science-driven company whose trajectory can be completely disconnected from general market trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization argenx SE
The medium-term market capitalization fluctuations of Argenx SE (ARGX) reflect its high sensitivity to the clinical success and commercialization of its immunology drugs. The Perf_Month_Co chart shows the market's reaction to trial phases, regulatory approvals, and early sales of key drugs, reflecting the risky but potentially highly rewarding operating cycle of biotech companies.
Monthly dynamics of market capitalization of the market segment - Pharma immune
This chart reflects the dynamics of the biotech sector. For Argenx, with its breakthrough drug for rare autoimmune diseases, it's the backdrop. Its impressive growth in a volatile sector demonstrates the strength of its scientific platform and commercial success.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Argenx SE is a biopharmaceutical company focused on developing drugs for severe autoimmune diseases. The company's future depends on the success of its clinical trials and sales, not on general economic trends. The broader market chart serves only as a backdrop, showing how news about Argenx's drugs has driven its stock price completely independently of the rest of the world.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization argenx SE
The weekly performance of Argenx, a biotech focused on treating autoimmune diseases, is a story of scientific breakthroughs and high expectations. Share prices are highly volatile, responding to clinical trial data, regulatory approvals, and the commercial success of their innovative drugs.
Weekly dynamics of market capitalization of the market segment - Pharma immune
The immunology sector in biotech is a field where scientific breakthroughs drive the entire market. Weekly performance depends on clinical trial data and regulatory approvals. The chart illustrates this highly volatile backdrop, making Argenx's success particularly impressive.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Argenx is a Belgian biotech company specializing in the treatment of rare autoimmune diseases. Shares of such innovative companies often move independently of the market, responding to scientific data. This chart will help you understand: is Argenx living in its own world of clinical trials, or is the overall market environment influencing its stock price?
Market capitalization of the company, segment and market as a whole
ARGX - Market capitalization of the company argenx SE
Argenx's market capitalization tells the story of a scientific breakthrough in the treatment of rare autoimmune diseases. The explosive growth on the chart reflects the commercial success of its first drug, Vyvgart, and investors' confidence in the potential of the entire technology platform. The market's assessment of the company's potential to become a new leader in immunology is reflected in the price movement.
ARGX - Share of the company's market capitalization argenx SE within the market segment - Pharma immune
Argenx is a biotech company specializing in developing drugs to treat severe autoimmune diseases. Its market share reflects the success of its antibody platform and breakthrough drug Vyvgart. The chart illustrates how a focus on innovative science can lead to the creation of a company with a massive market capitalization.
Market capitalization of the market segment - Pharma immune
Argenx is a biopharmaceutical company specializing in developing drugs for severe autoimmune diseases. The chart below shows the overall market capitalization of the biotech sector. Its volatility reflects the high stakes of the industry, where a single successful drug, like Argenx's, can transform the company into a multibillion-dollar behemoth.
Market capitalization of all companies included in a broad market index - GURU.Markets
Argenx is a biotech company specializing in the treatment of rare autoimmune diseases. Its high market cap is based on the potential of its innovative drug discovery platform. Its growth reflects the promise of breakthroughs in the treatment of complex diseases, which translates into enormous economic value.
Book value capitalization of the company, segment and market as a whole
ARGX - Book value capitalization of the company argenx SE
Argenx, a biopharmaceutical company, has a balance sheet comprised of its research laboratories, patents for its unique antibody technology, and capital for conducting expensive clinical trials. This is a tangible, science-intensive foundation aimed at creating drugs for rare diseases. How has this innovative capital grown? The chart below shows its development dynamics.
ARGX - Share of the company's book capitalization argenx SE within the market segment - Pharma immune
The biopharmaceutical company Argenx develops innovative treatments, which requires cutting-edge laboratories and research centers. The chart shows the share of these science-intensive tangible assets in the sector, reflecting the physical foundation upon which breakthrough therapies are created.
Market segment balance sheet capitalization - Pharma immune
Biopharmaceuticals are primarily science, which makes Argenx a relatively "lightweight" company. Its value lies in its patents and clinical data, not its manufacturing plants. Compared to the assets of the entire pharmaceutical sector, its model appears very capital-efficient, especially at the R&D stage.
Book value of all companies included in the broad market index - GURU.Markets
Argenx's assets are not giant factories, but cutting-edge biotech laboratories and research centers focused on developing drugs for rare autoimmune diseases. Its book value reflects its scientific capital and potential for developing innovative therapies. The chart shows the physical size of this rising biotech star.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - argenx SE
The market capitalization of Argenx, a biotech company, is a multiple of its book value. Investors are paying not for its labs, but for the potential of its platform for developing drugs for rare autoimmune diseases, which has already spawned one blockbuster.
Market to book capitalization ratio in a market segment - Pharma immune
Argenx is a biotech company specializing in the treatment of rare autoimmune diseases. Its value lies in its scientific platform and development pipeline. This chart clearly demonstrates how, in biotech, market valuation reflects investor confidence in the future commercial success of its innovative treatments.
Market to book capitalization ratio for the market as a whole
Argenx is a biotech company specializing in developing llama-based therapies for severe autoimmune diseases. Its value is determined not by its current assets, but by the potential of its scientific platform. This metric illustrates how expectations for future medical breakthroughs can lead to valuations that exceed book value by multiples.
Debts of the company, segment and market as a whole
ARGX - Company debts argenx SE
Argenx, a biotech company specializing in the treatment of autoimmune diseases, is in the commercialization phase of its first drug. The company is raising capital, including debt, to fund expensive research and the global launch of its product. This chart illustrates the financial strategy of the growing biotech.
Market segment debts - Pharma immune
Argenx is a biotech company specializing in developing antibodies to treat rare autoimmune diseases. Bringing such innovative drugs to market requires significant investment in research and clinical trials. This chart shows Argenx's financial strategy: how it uses capital raised, including debt, to finance its product portfolio.
Market debt in general
Argenx is a biotech company specializing in developing treatments for severe autoimmune diseases. While still in the commercialization stage of its first drugs, the company can incur significant expenses. This chart helps understand how Argenx finances its expensive research and market entry compared to more mature companies in other sectors.
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio argenx SE
Argenx, a biopharmaceutical company focused on treating rare autoimmune diseases, requires significant investment in research. This chart shows how the company funds its expensive research and development activities. It helps investors assess its dependence on external capital and the financial risks involved in commercializing new drugs.
Market segment debt to market segment book capitalization - Pharma immune
Argenx, a biotech company specializing in developing drugs to treat severe autoimmune diseases, compares its debt to the overall market capitalization of the pharmaceutical sector. It shows how the company finances its cutting-edge research and the launch of new drugs, which are key to its long-term success.
Debt to book value of all companies in the market
Argenx, a biotech company, is at the forefront of science. This chart compares its debt position to the overall market capitalization. It allows one to assess how the company's financial strategy, which depends on the success of long-term developments, is insulated from short-term economic cycles that affect the broader market.
P/E of the company, segment and market as a whole
P/E - argenx SE
Argenx is a biotech company specializing in developing antibodies to treat severe autoimmune diseases. This chart shows the very high valuation investors are placing on its innovative platform and the successful launch of its first drug. The premium reflects the high expectations for future drugs in its pipeline.
P/E of the market segment - Pharma immune
Argenx is a global immunology company developing innovative treatments for severe autoimmune diseases. Its approach is based on the creation of antibodies similar to those found in llamas and alpacas. This chart shows the average valuation for the pharmaceutical sector, helping to understand the market's perceived value in Argenx's cutting-edge scientific developments.
P/E of the market as a whole
Argenx is a biotech company specializing in the treatment of rare autoimmune diseases. Its success hinges on a key drug and future developments. Does the company's valuation exist in its own world of clinical data and commercial success, or does the overall market sentiment reflected in this chart influence investor risk appetite?
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company argenx SE
Argenx is a biotech company specializing in developing drugs to treat rare autoimmune diseases. This chart reflects investor expectations for its innovative platform and the commercial potential of its drugs. It assesses the company's potential to become a leader in its therapeutic niche.
%20P%2FE%20argenx%20SE&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-argenx-SE&v=1772624136101 "Chart of the company's future (projected) P/E argenx SE")
Future (projected) P/E of the market segment - Pharma immune
Argenx is a biotech company specializing in developing treatments for severe autoimmune diseases based on antibodies from llamas and alpacas. This chart shows how the market views Argenx's profitability prospects, reflecting expectations for the commercial success of its first drug, Vyvgart, and the potential of other developments in this innovative field.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-immune&v=1772624136274 "Future (projected) P/E graph of the market segment - Pharma immune")
Future (projected) P/E of the market as a whole
Argenx is a biotech company specializing in the treatment of severe autoimmune diseases. Its valuation is based on the success of its current drugs and the potential of future developments. This market sentiment chart provides the backdrop against which investors evaluate Argenx's scientific breakthroughs and commercial potential.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772624136329 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit argenx SE
Argenx is a biotech company specializing in the development of antibodies for the treatment of rare autoimmune diseases. This graph shows the path from research to commercialization of a breakthrough drug. Revenue growth will depend on the successful launch of new drugs and the expansion of indications for existing ones.
Profit of companies in the market segment - Pharma immune
Argenx is a biopharmaceutical company specializing in the development of drugs to treat severe autoimmune diseases. This chart shows its profitability in the immunology sector. The company's success, based on deep scientific research and the development of innovative treatments, makes it a leader in one of the most complex areas of medicine.
Overall market profit
Argenx is a biopharmaceutical company specializing in the treatment of rare autoimmune diseases. Demand for its innovative drugs is driven by medical indications, not the economy. However, the overall economic situation, reflected in this chart, impacts healthcare budgets and their ability to cover expensive treatments.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company argenx SE
Argenx SE is a biotech company specializing in developing llama-based therapies for severe autoimmune diseases. This chart reflects analysts' expectations for future revenue. The forecast is dependent on the successful sales of its flagship drug, Vyvgart, and its expansion into other diseases.
%20profit%20of%20the%20company%20argenx%20SE&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-argenx-SE&v=1772624136480 "Graph of future (projected) profit of the company argenx SE")
Future (predicted) profit of companies in the market segment - Pharma immune
Argenx is a biotechnology company specializing in the development of drugs to treat severe autoimmune diseases. The revenue forecasts for the immunology pharmaceutical segment shown here reflect scientific progress in this area. This chart provides context for assessing the potential of the company's flagship drug and its future developments.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-immune&v=1772624136549 "Graph of future (predicted) profits of companies in a market segment - Pharma immune")
Future (predicted) profit of the market as a whole
Argenx is a biotech company specializing in developing drugs to treat severe autoimmune diseases. Demand for its innovative drugs isn't directly dependent on economic cycles. However, the positive overall backdrop reflected in this chart improves investor sentiment and facilitates raising capital for further research.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772624136587 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - argenx SE
Argenx is a biotech company specializing in the treatment of rare autoimmune diseases. For companies like this, this chart is especially important. It shows the enormous premium investors are paying for the current and future sales of their innovative drugs, betting that their scientific platform will become the basis for a whole new class of drugs.
P/S market segment - Pharma immune
Argenx is a biotech company specializing in developing antibody-based treatments for severe autoimmune diseases. Its success depends on its innovative scientific platform and drug commercialization. This chart shows the average valuation in the sector, helping to understand the premium investors are placing on Argenx's scientific potential and future revenue.
P/S of the market as a whole
Argenx is a biotech company specializing in developing drugs to treat severe autoimmune diseases. Its approach is based on mimicking the immune system of llamas to create antibodies. This chart helps understand how investors value the revenue of this innovative biotech company with a breakthrough platform compared to the overall market.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company argenx SE
Argenx is a biotech company specializing in developing treatments for severe autoimmune diseases. This chart reflects investors' high estimates of its future revenue. This estimate is based on the success of its first drug and the significant potential of its scientific platform for developing new drugs.
%20P%2FS%20argenx%20SE&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-argenx-SE&v=1772624136857 "The graph of the company's future (projected) P/S argenx SE")
Future (projected) P/S of the market segment - Pharma immune
Argenx is a global immunology company developing innovative treatments for severe autoimmune diseases. This chart compares the company's estimated future sales with other immunotherapy companies. It reflects market expectations for the commercial success of its flagship drug and the potential of its research platform to develop new drugs.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20immune&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-immune&v=1772624136929 "Future (projected) P/S market segment graph - Pharma immune")
Future (projected) P/S of the market as a whole
Argenx is a biotech company specializing in developing treatments for rare autoimmune diseases. Its value is based on the potential of its scientific developments and the success of its flagship drug. This chart of overall market expectations for Argenx is merely a backdrop, as its growth is determined by clinical data and regulatory approvals, not the state of the economy.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772624136935 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales argenx SE
This chart shows the revenue of Argenx, a biotech company specializing in the treatment of rare autoimmune diseases. Revenue is generated by sales of its innovative drug based on llama antibodies. The rapid revenue growth in this chart demonstrates the successful launch of this breakthrough product and the high unmet demand for effective treatments in this complex area of medicine.
Sales of companies in the market segment - Pharma immune
Argenx is a biotech company specializing in developing treatments for severe autoimmune diseases. Its approach is based on creating antibodies similar to those found in llamas and alpacas. This chart shows revenue in the immunological pharmaceuticals sector. It reflects the growing demand for innovative targeted therapies for rare diseases, where Argenx occupies a unique niche.
Overall market sales
Argenx is a biotech company specializing in developing antibodies to treat severe autoimmune diseases. Demand for its innovative drugs is driven by medical needs, not economic cycles. However, long-term economic growth, as shown in this chart, ensures the solvency of healthcare systems, allowing them to cover expensive treatments.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company argenx SE
Argenx is a biotechnology company specializing in the development of drugs for the treatment of severe autoimmune diseases. This revenue forecast chart reflects expectations for the commercial success of its lead drug. The sharp increase in this figure is driven by sales forecasts and approvals for its use in the treatment of new diseases.
%20sales%20of%20the%20company%20argenx%20SE&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-argenx-SE&v=1772624137116 "Schedule of future (projected) sales of the company argenx SE")
Future (projected) sales of companies in the market segment - Pharma immune
Argenx is a biotech company specializing in developing treatments for severe autoimmune diseases. Their approach is based on creating antibodies that mimic the immune systems of llamas and camels. This chart shows projected revenues for the entire immunopharmaceutical sector, reflecting expectations for breakthrough treatments in this complex area of medicine.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-immune&v=1772624137175 "Schedule of future (projected) sales of companies in the market segment - Pharma immune")
Future (projected) sales of the market as a whole
Argenx is a biotech company specializing in the treatment of rare autoimmune diseases. While demand for its drugs is driven by medical needs rather than economics, overall market conditions influence investor sentiment and the availability of capital to fund the expensive research that underpins the company's growth.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772624137219 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality argenx SE
Argenx is a biotech company specializing in the development of antibodies to treat severe autoimmune diseases. This chart illustrates its transition from a research-stage company to a commercial organization. The growth of this indicator is directly related to the successful launch and sales growth of its first drug, which paves the way to sustainable profitability.
Market segment marginality - Pharma immune
Argenx is a biotech company specializing in developing drugs to treat severe autoimmune diseases. Its success depends on the profitability of approved drugs based on its innovative platform. This chart shows the average profitability in the pharmaceutical industry. It allows one to assess the potential of Argenx's research and development to create breakthrough and profitable treatments.
Market marginality as a whole
Argenx is a biopharmaceutical company specializing in the development of treatments for rare autoimmune diseases. Its success is determined not by the general economic cycles shown in the chart, but by breakthroughs in scientific research and the successful commercialization of its developments. Demand for its unique drugs is inelastic, as they address critical medical problems.
Employees in the company, segment and market as a whole
Number of employees in the company argenx SE
Argenx is a biotech company specializing in the treatment of rare autoimmune diseases using an innovative antibody platform. Scientific breakthroughs require talent. This chart shows how the company is growing its team of scientists and clinicians to bring new drugs to market and realize the potential of its technology.
Share of the company's employees argenx SE within the market segment - Pharma immune
Argenx is a clinical-stage immunology company. As a biotech focused on research and development, its most valuable asset is its team of scientists. This chart will demonstrate its scale not in production, but in innovation, measuring the concentration of specialized talent in the competitive field of immunology research that it attracts.
Number of employees in the market segment - Pharma immune
Argenx is a biotech company specializing in the development of antibodies to treat rare autoimmune diseases. This timeline shows the path from a scientific idea to a commercial product. The rapid growth of staff after the approval of the first drug reflects the need to quickly establish a global sales and marketing system to bring an innovative drug to market.
Number of employees in the market as a whole
Argenx is a biotechnology company specializing in the treatment of rare autoimmune diseases. The growth of its world-class scientific team reflects the enormous potential and investment being made in immunology research, one of the most advanced fields of medicine.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company argenx SE (ARGX)
Argenx is a biotech company developing innovative antibody-based drugs. Their market capitalization is built on the success of their scientific platform. This is an astronomical figure for them. The success of a single drug can generate tens of billions of dollars in value. The market values the potential of their R&D, where every scientist is worth their weight in gold.
%20of%20the%20company%20argenx%20SE%20(ARGX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-argenx-SE-ARGX&v=1772624137513 "Chart of market capitalization per employee (in thousands of dollars) of the company argenx SE (ARGX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma immune
Argenx is a biotech company specializing in the treatment of rare autoimmune diseases. Like Alnylam, it's a pure R&D business, where all the value comes from science and patents. This metric, compared to the industry average, reflects the significant premium the market pays for their innovative platform and the potential for future drugs per scientist.
%20by%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-immune&v=1772624137527 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma immune")
Market capitalization per employee (in thousands of dollars) for the overall market
Argenx is a biopharmaceutical company specializing in the treatment of rare autoimmune diseases. This chart demonstrates how a focus on cutting-edge science and a narrow niche creates enormous value. The team's efforts lead to the creation of breakthrough drugs, giving the company one of the highest market valuations per employee.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772624137572 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company argenx SE (ARGX)
Argenx SE is a biotech company focused on developing drugs for rare autoimmune diseases. Their business is cutting-edge science. This chart shows how successfully the company is commercializing its R&D. For biotech companies, high profit per employee is a sign that their blockbuster drugs have reached the market and command a high price.
%20Chart%20argenx%20SE%20(ARGX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-argenx-SE-ARGX&v=1772624137579 "Company Profit Per Employee (in thousands of dollars) Chart argenx SE (ARGX)")
Profit per employee (in thousands of dollars) in the market segment - Pharma immune
Argenx is a biotech company focused on autoimmune diseases. This chart shows the benchmark for "immune pharma." The average profit per employee in this sector (biotech) is astronomical. It's a "blockbuster business." A single successful patent for a drug for a rare disease can generate billions, recouping all R&D.
%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-immune&v=1772624137630 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma immune")
Profit per employee (in thousands of dollars) for the market as a whole
Argenx is a biotech company specializing in developing drugs for the treatment of severe autoimmune diseases based on llama antibodies. This cutting-edge science requires unique competencies. This graph illustrates the enormous value per scientist that this breakthrough science-intensive industry can generate.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772624137659 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee argenx SE (ARGX)
Argenx is a biotech company specializing in the treatment of rare autoimmune diseases. This chart illustrates the economics of successfully launching a blockbuster niche drug. The astronomical revenue per employee reflects the high price and value of this innovative, life-changing drug.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-argenx-SE-ARGX&v=1772624137733 "Sales chart per company employee argenx SE (ARGX)")
Sales per employee in the market segment - Pharma immune
Argenx is a biotech company focused on developing drugs to treat severe autoimmune diseases. Their business is focused on cutting-edge science (R&D) and bringing blockbusters to market. This chart shows the industry average per employee income. It helps assess how commercially viable Argenx's R&D is compared to other companies.
Sales per employee for the market as a whole
Argenx is a biotech company specializing in the treatment of severe autoimmune diseases. Their core business is cutting-edge immunology and R&D. This metric reflects how their team of scientists creates and commercializes highly specialized, high-value drugs (like their blockbuster Vyvgart), generating high revenue per employee.
Short shares by company, segment and market as a whole
Shares shorted by company argenx SE (ARGX)
Argenx is a biotech company developing treatments for severe autoimmune diseases. This chart shows the volume of bets against it. Bears may doubt the success of its key drug, Vyvgart, against competitors or fear the inherent risks of biotech, where a trial failure could send the stock plummeting.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-argenx-SE-ARGX&v=1772624137842 "Short Shares Chart for the Company argenx SE (ARGX)")
Shares shorted by market segment - Pharma immune
Argenx is a biotech company specializing in developing treatments for severe autoimmune diseases based on llama antibodies. This indicator reflects skepticism. "Shorting" Argenx represents a bet on biotech risk. Investors may be betting that their key drug, Vyvgart, will face stiff competition or that new drugs in development will fail clinical trials.
Shares shorted by the overall market
Argenx is a biotech company focused on treating rare autoimmune diseases. It's a high-risk, high-reward sector. This indicator of market fear is critical for biotech. When pessimism increases, the funding tap for unprofitable but innovative companies is turned off. Investors flee speculative growth in favor of real profits.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator argenx SE (ARGX)
Argenx, a biopharmaceutical company focusing on rare autoimmune diseases, depends on the success of its drugs. This indicator, above 70, may reflect strong sales or positive trial data. Oversold territory (<30) is often associated with competitive concerns or regulatory risks.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-argenx-SE-ARGX&v=1772624138089 "RSI 14 indicator chart for the company's stock argenx SE (ARGX)")
RSI 14 Market Segment - Pharma immune
Argenx (ARGX) is a biotech company specializing in autoimmune diseases, whose flagship drug, Vyvgart, has become a blockbuster. This chart shows the overall sentiment in the biotech sector. It helps us understand: is ARGX overexposed to the market by Vyvgart's success, or is the entire sector overbought by the M&A wave?
RSI 14 for the overall market
Argenx is a biotech company specializing in developing treatments for severe autoimmune diseases. Biotech stocks are highly volatile and depend on the success of clinical trials. This chart shows the overall market "temperature." It helps distinguish Argenx's movements driven by news about its drugs from general market panic or euphoria in the healthcare sector.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ARGX (argenx SE)
Argenx is a biotech company specializing in the treatment of severe autoimmune diseases. Their key drug, Vyvgart, is experiencing rapid growth. This chart reflects the collective opinion of Wall Street. It shows the average target price based on peak sales forecasts for Vyvgart and their R&D success in creating new blockbusters.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ARGX-argenx-SE&v=1772624138214 "A chart showing analyst consensus forecasts for the expected stock price. ARGX (argenx SE)")
The difference between the consensus estimate and the actual stock price ARGX (argenx SE)
Argenx (ARGX) is a biotech company developing innovative antibody-based treatments for severe autoimmune diseases. This chart is a barometer of hope. It shows the difference between the price and the consensus target, reflecting analysts' confidence in the success of their lead drug, Vyvgart, and its potential to become a blockbuster.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ARGX-argenx-SE&v=1772624138223 "A chart showing the difference between the consensus forecast and the actual stock price. ARGX (argenx SE)")
Analyst consensus forecast for stock prices by market segment - Pharma immune
Argenx is a European biotech company that has made a breakthrough in the treatment of rare autoimmune diseases (Vyvgart). This chart shows analysts' overall expectations for the entire biotech sector. It reflects whether experts believe new, expensive drugs will succeed or whether they believe the sector is overheated.
Analysts' consensus forecast for the overall market share price
Argenx SE is a biotech company specializing in developing antibody-based treatments for severe autoimmune diseases. Their success depends on clinical trials and drug approvals. This chart shows general market expectations. For a biotech like Argenx, overall market sentiment is important for raising capital, but the stock price primarily responds to scientific data, not the overall market.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index argenx SE
Argenx is a biotech company specializing in developing drugs to treat severe autoimmune diseases. Their success is built on their antibody platform. This chart is a classic biotech story. It reflects the market's high expectations for their flagship drug, Vyvgart, and the potential of their R&D platform to create new blockbusters.
AKIMA Market Segment Index - Pharma immune
Argenx SE is a Belgian biotech focused on immunology, which achieved tremendous success with its blockbuster drug Vyvgart for the treatment of rare autoimmune diseases. This summary metric evaluates R&D. The graph shows the segment average. This benchmark: how does Argenx's breakthrough platform differentiate it from the average pharma company?
The AKIM Index for the overall market
Argenx is a biotech company specializing in developing antibody-based treatments for severe autoimmune diseases. Its first drug, Vyvgart, was a blockbuster. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this innovative scientific story, driven by the laws of biotech, compares to the broader economic trends that influence investor risk appetite.
